Morbidity, mortality, and management of methicillin-resistant S. aureus bacteremia in the USA: update on antibacterial choices and understanding

Jessica K. Ortwine, Kavita Bhavan

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with significant healthcare costs, morbidity, and mortality in the United States. Complications of MRSA bacteremia include infective endocarditis, osteomyelitis, and sepsis, all of which are difficult to treat. Time to effective therapy and antibacterial choice greatly affect patient outcomes. Vancomycin and daptomycin remain first-line therapies; however, reports of vancomycin-associated treatment failure and reduced daptomycin susceptibility highlight the need to define alternative strategies for MRSA bacteremia treatment. In addition, several patient- and pathogen-specific factors influence the outcomes of MRSA bacteremia. It is, therefore, critical to explore the interaction between host- and pathogen-specific factors and its effect on MRSA bacteremia pathogenesis and mortality. This review discusses the factors that drive the development of MRSA bacteremia and examines alternative treatment strategies.

Original languageEnglish (US)
Pages (from-to)64-72
Number of pages9
JournalHospital practice (1995)
Volume46
Issue number2
DOIs
StatePublished - Apr 1 2018

Fingerprint

Methicillin Resistance
Methicillin-Resistant Staphylococcus aureus
Bacteremia
Morbidity
Mortality
Daptomycin
Vancomycin
Host-Pathogen Interactions
Osteomyelitis
Therapeutics
Endocarditis
Treatment Failure
Health Care Costs
Sepsis

Keywords

  • Bacteremia
  • ceftaroline
  • dalbavancin
  • daptomycin
  • linezolid
  • methicillin-resistant S. aureus
  • oritavancin
  • Staphylococcus aureus
  • telavancin
  • vancomycin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Morbidity, mortality, and management of methicillin-resistant S. aureus bacteremia in the USA : update on antibacterial choices and understanding. / Ortwine, Jessica K.; Bhavan, Kavita.

In: Hospital practice (1995), Vol. 46, No. 2, 01.04.2018, p. 64-72.

Research output: Contribution to journalReview article

@article{fe59d02483184c168407b2ae5cb7a056,
title = "Morbidity, mortality, and management of methicillin-resistant S. aureus bacteremia in the USA: update on antibacterial choices and understanding",
abstract = "Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with significant healthcare costs, morbidity, and mortality in the United States. Complications of MRSA bacteremia include infective endocarditis, osteomyelitis, and sepsis, all of which are difficult to treat. Time to effective therapy and antibacterial choice greatly affect patient outcomes. Vancomycin and daptomycin remain first-line therapies; however, reports of vancomycin-associated treatment failure and reduced daptomycin susceptibility highlight the need to define alternative strategies for MRSA bacteremia treatment. In addition, several patient- and pathogen-specific factors influence the outcomes of MRSA bacteremia. It is, therefore, critical to explore the interaction between host- and pathogen-specific factors and its effect on MRSA bacteremia pathogenesis and mortality. This review discusses the factors that drive the development of MRSA bacteremia and examines alternative treatment strategies.",
keywords = "Bacteremia, ceftaroline, dalbavancin, daptomycin, linezolid, methicillin-resistant S. aureus, oritavancin, Staphylococcus aureus, telavancin, vancomycin",
author = "Ortwine, {Jessica K.} and Kavita Bhavan",
year = "2018",
month = "4",
day = "1",
doi = "10.1080/21548331.2018.1435128",
language = "English (US)",
volume = "46",
pages = "64--72",
journal = "Hospital practice (1995)",
issn = "2154-8331",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Morbidity, mortality, and management of methicillin-resistant S. aureus bacteremia in the USA

T2 - update on antibacterial choices and understanding

AU - Ortwine, Jessica K.

AU - Bhavan, Kavita

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with significant healthcare costs, morbidity, and mortality in the United States. Complications of MRSA bacteremia include infective endocarditis, osteomyelitis, and sepsis, all of which are difficult to treat. Time to effective therapy and antibacterial choice greatly affect patient outcomes. Vancomycin and daptomycin remain first-line therapies; however, reports of vancomycin-associated treatment failure and reduced daptomycin susceptibility highlight the need to define alternative strategies for MRSA bacteremia treatment. In addition, several patient- and pathogen-specific factors influence the outcomes of MRSA bacteremia. It is, therefore, critical to explore the interaction between host- and pathogen-specific factors and its effect on MRSA bacteremia pathogenesis and mortality. This review discusses the factors that drive the development of MRSA bacteremia and examines alternative treatment strategies.

AB - Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with significant healthcare costs, morbidity, and mortality in the United States. Complications of MRSA bacteremia include infective endocarditis, osteomyelitis, and sepsis, all of which are difficult to treat. Time to effective therapy and antibacterial choice greatly affect patient outcomes. Vancomycin and daptomycin remain first-line therapies; however, reports of vancomycin-associated treatment failure and reduced daptomycin susceptibility highlight the need to define alternative strategies for MRSA bacteremia treatment. In addition, several patient- and pathogen-specific factors influence the outcomes of MRSA bacteremia. It is, therefore, critical to explore the interaction between host- and pathogen-specific factors and its effect on MRSA bacteremia pathogenesis and mortality. This review discusses the factors that drive the development of MRSA bacteremia and examines alternative treatment strategies.

KW - Bacteremia

KW - ceftaroline

KW - dalbavancin

KW - daptomycin

KW - linezolid

KW - methicillin-resistant S. aureus

KW - oritavancin

KW - Staphylococcus aureus

KW - telavancin

KW - vancomycin

UR - http://www.scopus.com/inward/record.url?scp=85045214908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045214908&partnerID=8YFLogxK

U2 - 10.1080/21548331.2018.1435128

DO - 10.1080/21548331.2018.1435128

M3 - Review article

C2 - 29400119

AN - SCOPUS:85045214908

VL - 46

SP - 64

EP - 72

JO - Hospital practice (1995)

JF - Hospital practice (1995)

SN - 2154-8331

IS - 2

ER -